Quiniodochlor
The properties are similar to clioquinol, so see below at clioquinol record for the details.
Clioquinol; Hydrocortisone
Indications: Acne urticata; Candidiasis, topical; Dermatitis, atopic; Dermatitis, chronic infectious; Dermatitis, contact; Dermatitis, stasis; Eczema, infantile; Eczema, nuchal; Eczema, nummular; Eczema, pustulosum; Folliculitis; Infection, ear, external; Infection, skin and skin structures; Intertrigo; Lichen simplex chronicus; Neurodermatitis; Pruritus, anogenital; Pyoderma; Tinea capitis; Tinea corporis; Tinea cruris; Tinea pedis
DESCRIPTION:
Vioform-Hydrocortisone, a topical compound for dermatologic use, combines the antifungal and antibacterial actions of clioquinol USP and the anti-inflammatory and antipruritic effects of hydrocortisone USP to provide broad control of acute and chronic dermatoses. It is available as cream, or ointment, containing 3% clioquinol USP and 1% hydrocortisone USP and as mild cream containing 3% clioquinol USP and 0.5% hydrocortisone USP.
Vioform is 5-chloro-7-iodo-8-quinolinol. Hydrocortisone is 11beta, 17, 21-trihydroxypregn-4-ene-3,20-dione.
CLINICAL PHARMACOLOGY:
In vitro studies have demonstrated than clioquinol and hydrocorisone effectively inhibits the growth of various mycotic organisms such as Microsporons, Trichophytons, and Candida albicans and gram positive cocci such as staphylococci and enterococci .
The role of steroids in alleviating the inflammation and pruritus associated with many dermatoses has been well established.
INDICATIONS AND USAGE:
Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the indications as follows:
"Possibly" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis; intertrigo.
Final classification of the less-than-effective indications requires further investigation.
CONTRAINDICATIONS:
Hypersensitivity to clioquinol and hydrocorisone, or any of its ingredients or related compounds; lesions of the eye; tuberculosis of the skin; most viral skin lesions (including herpes simplex, vaccinia, and varicella).
Clioquinol and hydrocorisone should not be used in children under 2 years of age. Clioquinol and hydrocorisone should not be used for diaper rash.
WARNINGS:
This product is not for ophthalmic use.
In the presence of systemic infections, appropriate systemic antibiotics should be used.
Usage in Pregnancy
Although topical steroids have not been reported to have an adverse effect on pregnancy, the safety of their use in pregnant women has not been absolutely established. In laboratory animals, increases in incidence of fetal abnormalities have been associated with exposure of gestating females to topical corticosteroids, in some cases at rather low dosage levels. Therefore, drugs of this class should not be used extensively on pregnant patients in large amounts or for prolonged periods of time.
PRECAUTIONS:
May prove irritating to sensitized skin in rare cases. If irritation occurs, discontinue therapy. Staining of skin and fabrics may occur. Additionally, there are rare reports of discoloration of hair and nails.
Signs and symptoms of systemic toxicity, electrolyte imbalance, or adrenal suppression have not been reported with clioquinol and hydrocorisone. Nevertheless, the possibility of suppression of the pituitary-adrenal axis during therapy should be kept in mind, especially when the drug is used under occlusive dressings, for a prolonged period, or for treating extensive cutaneous areas since significant absorption of corticosteroid may occur under these conditions, particularly in children and infants.
Clioquinol and hydrocorisone may be absorbed through the skin and interfere with thyroid function tests. If such tests are contemplated, wait at least one month between discontinuation of therapy and performance of these tests. The ferric chloride test for phenylketonuria (PKU) can yield a false-positive result if clioquinol and hydrocorisone is present in the diaper or urine.
Prolonged use may result in overgrowth of nonsusceptible organism requiring appropriate therapy.
ADVERSE REACTIONS:
There have been a few reports of rash and hypersensitivity.
The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning; itching; irritation; dryness; folliculitis; hypertrichosis; acneiform eruptions; hypopigmentation; perioral dermatitis; allergic contact dermatitis; maceration of the skin; secondary infection; skin atrophy; striae; miliaria.